Metallothionein 2A-Silencing Antimonene-Based Nanoagonist for Amplifying the Photothermal Immunotherapy of Gynecologic Malignancy.

ACS Nano

State Key Laboratory of Flexible Electronics (LoFE) & Jiangsu Key Laboratory of Smart Biomaterials and Theranostic Technology, Institute of Advanced Materials (IAM), School of Chemistry and Life Sciences, College of Electronic and Optical Engineering & College of Flexible Electronics (Future Technol

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Gynecologic malignancies are prone to metastasis and recurrence due to the low efficacy and sensitivity of current clinical treatments. Here, we construct ultrasmall Sb@Au nanodots (Sb@Au NDs) as a metallothionein 2A (MT 2A)-silencing nanoagonist for effective photothermal immunotherapy of gynecologic malignancies. Sb@Au NDs show high photothermal conversion efficiency of 56.8% under a 1270 nm laser and exceptional capability for downregulating MT 2A overexpressed in gynecologic malignancies. Synergizing mild photothermal therapy (PTT) with targeting downregulation of MT 2A based on Sb@Au NDs offers a robust therapeutic effect, significantly activating adaptive immune response and inhibiting the metastasis of gynecologic malignancies. RNA sequencing results of SKOV-3 cells elucidate that MT 2A downregulation by Sb@Au NDs impedes the transcription of zinc finger protein genes, thereby triggering the TGF-β signaling pathway, which blocks the cell cycle and activates the MAPK/c-fos apoptotic pathway to sensitize the treatment of gynecologic malignancies. Mild PTT synergizing with MT 2A downregulation by Sb@Au NDs can promote the secretion of β-defensin to increase the infiltration of CD4 and CD8 T cells and potentiate T-cell-mediated adaptive immune response. Our work provides an MT 2A-silencing nanoagonist for highly effective combination therapy and metastasis inhibition of gynecologic malignancies.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsnano.5c07692DOI Listing

Publication Analysis

Top Keywords

gynecologic malignancies
24
sb@au nds
20
metallothionein 2a-silencing
8
photothermal immunotherapy
8
immunotherapy gynecologic
8
2a-silencing nanoagonist
8
adaptive immune
8
immune response
8
downregulation sb@au
8
gynecologic
7

Similar Publications

Background: Robotic single-port transvaginal natural orifice transluminal endoscopic surgery (RSP-vNOTES) is an emerging minimally invasive approach that combines the advantages of robotic surgery with scarless transvaginal access. Its application in gynecologic oncology remains limited, particularly for omentectomy during ovarian cancer staging.

Methods: We present the case of a 45-year-old woman with an ovarian granulosa cell tumor (GCT) who underwent supplemental staging surgery following unilateral oophorectomy.

View Article and Find Full Text PDF

Background: Ovarian mature teratomas (OMTs) are the most common benign ovarian tumors in pediatric patients. Management in adolescents can be performed by pediatric (PSs) or gynecologic surgeons (GSs). The aim of this study was to assess the differences in OMT management and the repercussions according to the risk of secondary events.

View Article and Find Full Text PDF

Uterine leiomyosarcoma (uLMS) is a rare and deadly gynecologic malignancy. uLMS is histologically heterogeneous and presents with a wide spectrum of tumor differentiation, with a broad range of genomic DNA instability, which can make the diagnosis and prognosis of uLMS challenging. Methylation has emerged as a useful molecular tool in tumor classification and diagnosis in certain neoplasms.

View Article and Find Full Text PDF

Addition of metronidazole to standard-of-care perioperative prophylaxis at the time of hysterectomy for gynecologic malignancies.

Int J Gynecol Cancer

August 2025

Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Long Island Jewish Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New Hyde Park, NY, USA; Northwell Health, Feinstein Institutes for Medical Research, Institute of Molecular Medicine, Manhas

Objective: The purpose of this study was to evaluate whether the combination of cefazolin or a second-generation cephalosporin plus metronidazole is associated with a reduced risk of surgical site infection in women undergoing hysterectomy for gynecologic cancer compared to using cefazolin or a second-generation cephalosporin alone.

Methods: This was a retrospective cohort study of patients who underwent hysterectomy at a single institution between January 2020 and June 2022. The primary outcome was surgical site infection.

View Article and Find Full Text PDF

Metallothionein 2A-Silencing Antimonene-Based Nanoagonist for Amplifying the Photothermal Immunotherapy of Gynecologic Malignancy.

ACS Nano

September 2025

State Key Laboratory of Flexible Electronics (LoFE) & Jiangsu Key Laboratory of Smart Biomaterials and Theranostic Technology, Institute of Advanced Materials (IAM), School of Chemistry and Life Sciences, College of Electronic and Optical Engineering & College of Flexible Electronics (Future Technol

Gynecologic malignancies are prone to metastasis and recurrence due to the low efficacy and sensitivity of current clinical treatments. Here, we construct ultrasmall Sb@Au nanodots (Sb@Au NDs) as a metallothionein 2A (MT 2A)-silencing nanoagonist for effective photothermal immunotherapy of gynecologic malignancies. Sb@Au NDs show high photothermal conversion efficiency of 56.

View Article and Find Full Text PDF